{"id":"https://openalex.org/W2590910998","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps244","title":"Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients.","display_name":"Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients.","publication_year":2010,"publication_date":"2010-05-20","ids":{"openalex":"https://openalex.org/W2590910998","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps244","mag":"2590910998"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2010.28.15_suppl.tps244","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps244","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps244","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5026672076","display_name":"Geoffrey Thomas Gibney","orcid":"https://orcid.org/0000-0002-5401-8498","observed_orcids":["https://orcid.org/0000-0002-5401-8498"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"G. Gibney","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075719753","display_name":"Aymen A. Elfiky","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Elfiky","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070016877","display_name":"Christopher J. Hoimes","orcid":"https://orcid.org/0000-0001-8980-2410","observed_orcids":["https://orcid.org/0000-0001-8980-2410"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. J. Hoimes","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108790176","display_name":"Alexander W. R. Burns","orcid":"https://orcid.org/0000-0003-4970-0959","observed_orcids":["https://orcid.org/0000-0003-4970-0959"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Burns","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031631924","display_name":"Elin Rowen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"E. Rowen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"J. A. McDonough","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. A. McDonough","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109975154","display_name":"Rachel Lampert","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"R. Lampert","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044029313","display_name":"C. Gr\u00f6\u00df","orcid":"https://orcid.org/0000-0001-6566-333X","observed_orcids":["https://orcid.org/0000-0001-6566-333X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"C. Gross","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5108511133","display_name":"William Kevin Kelly","orcid":"https://orcid.org/0000-0003-2629-672X","observed_orcids":["https://orcid.org/0000-0003-2629-672X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"W. K. Kelly","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"28","issue":"15_suppl","first_page":"TPS244","last_page":"TPS244"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.38109999895095825,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","score":0.38109999895095825,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10745","display_name":"Heart Rate Variability and Autonomic Control","score":0.2678000032901764,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10543","display_name":"Prostate Cancer Treatment and Research","score":0.09589999914169312,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/heart-rate-variability","display_name":"heart rate variability","score":0.8569999933242798},{"id":"https://openalex.org/keywords/androgen-deprivation-therapy","display_name":"androgen deprivation therapy","score":0.9290000200271606},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/metastatic-prostate-cancer","display_name":"metastatic prostate cancer","score":0.949999988079071},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.6830000281333923},{"id":"https://openalex.org/keywords/autonomic-dysfunction","display_name":"autonomic dysfunction","score":0.9160000085830688},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.8349999785423279},{"id":"https://openalex.org/keywords/vascular-endothelial-growth-factor","display_name":"vascular endothelial growth factor","score":0.6869999766349792},{"id":"https://openalex.org/keywords/leuprolide-acetate","display_name":"leuprolide","score":0.7820000052452087},{"id":"https://openalex.org/keywords/goserelin","display_name":"goserelin","score":0.9679999947547913},{"id":"https://openalex.org/keywords/bicalutamide","display_name":"bicalutamide","score":0.9390000104904175},{"id":"https://openalex.org/keywords/holter-monitoring","display_name":"Holter monitoring","score":0.6790000200271606},{"id":"https://openalex.org/keywords/cardiac-biomarkers","display_name":"cardiac biomarkers","score":0.765999972820282},{"id":"https://openalex.org/keywords/psa-kinetics","display_name":"PSA kinetics","score":0.4650000035762787},{"id":"https://openalex.org/keywords/diabetes-risk","display_name":"diabetes risk","score":0.4230000078678131},{"id":"https://openalex.org/keywords/myocardial-infarction","display_name":"myocardial infarction","score":0.9440000057220459},{"id":"https://openalex.org/keywords/sudden-cardiac-arrest","display_name":"sudden cardiac arrest","score":0.8650000095367432},{"id":"https://openalex.org/keywords/endothelial-dysfunction","display_name":"endothelial dysfunction","score":0.3959999978542328}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9631695747375488},{"id":"https://openalex.org/C2777899217","wikidata":"https://www.wikidata.org/wiki/Q4759439","display_name":"Androgen deprivation therapy","level":4,"score":0.7944544553756714},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.7227835059165955},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.6930474638938904},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6068345308303833},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5017573833465576},{"id":"https://openalex.org/C2780962315","wikidata":"https://www.wikidata.org/wiki/Q1988832","display_name":"Bicalutamide","level":5,"score":0.49001991748809814},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.4848800599575043},{"id":"https://openalex.org/C500558357","wikidata":"https://www.wikidata.org/wiki/Q12152","display_name":"Myocardial infarction","level":2,"score":0.4779082238674164},{"id":"https://openalex.org/C2778043895","wikidata":"https://www.wikidata.org/wiki/Q1992653","display_name":"Goserelin","level":4,"score":0.427178293466568},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3808354139328003},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.32864177227020264},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.23396605253219604},{"id":"https://openalex.org/C61367390","wikidata":"https://www.wikidata.org/wiki/Q416601","display_name":"Androgen receptor","level":4,"score":0.20205575227737427},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2010.28.15_suppl.tps244","doi":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps244","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2010.28.15_suppl.tps244","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2265770229","https://openalex.org/W2130169437","https://openalex.org/W4308684837","https://openalex.org/W4393195091","https://openalex.org/W7098214952","https://openalex.org/W2915731681","https://openalex.org/W2747347785","https://openalex.org/W2301411256","https://openalex.org/W2990387776","https://openalex.org/W2979622683"],"abstract_inverted_index":{"TPS244":[0],"Background:":[1],"Androgen-deprivation":[2],"therapy":[3,74,172],"(ADT)":[4],"is":[5,31,140,155,262,288,297],"standard":[6],"treatment":[7],"in":[8,108,149,159],"noncastrate":[9],"patients":[10,86,192,216,321],"with":[11,18,45,88,142,164],"metastatic":[12,187],"or":[13,173,184,208,232,330,334],"recurrent":[14],"prostate":[15],"cancer":[16,160],"(PC)":[17],"a":[19,42,122,156,176,199],"median":[20],"duration":[21,301],"of":[22,24,65,72,94,180,186,302],"response":[23],"12-18":[25],"months.":[26,214],"Preclinical":[27],"data":[28],"shows":[29],"castration":[30],"correlated":[32],"to":[33,56,76,307,325],"decreased":[34],"vascular":[35],"endothelial":[36,311],"growth":[37],"factor":[38],"(VEGF)":[39],"expression":[40],"and":[41,47,61,69,81,99,148,175,198,229,271,273,281,291,300,313],"synergistic":[43],"effect":[44],"ADT":[46,89,230],"VEGF":[48],"inhibition":[49],"on":[50],"tumor":[51],"growth.":[52],"This":[53,115],"may":[54],"lead":[55],"increased":[57,92],"PC":[58,85],"cell":[59,314],"death":[60],"prolonged":[62],"therapeutic":[63],"effects":[64,71],"medical":[66],"castration.":[67],"Safety":[68],"biological":[70],"combination":[73],"need":[75],"be":[77,129],"established.":[78],"SEER":[79],"database":[80],"other":[82],"studies":[83,306],"show":[84],"treated":[87,113],"were":[90],"at":[91],"risk":[93],"diabetes,":[95],"myocardial":[96],"infarction":[97],"(MI)":[98],"sudden":[100],"cardiac":[101,144,196,266],"arrest.":[102],"Cardiovascular":[103,260],"events":[104],"are":[105,189,217,318],"more":[106],"prevalent":[107],"anti-VEGF":[109],"antibody":[110],"(bevacizumab;":[111],"BEV)":[112],"patients.":[114,161],"study":[116],"will":[117],"assess":[118,308],"autonomic":[119],"dysregulation":[120],"as":[121],"predictor":[123],"for":[124,219,237,255,283],"cardiovascular":[125,289],"outcomes,":[126],"which":[127],"can":[128],"achieved":[130],"via":[131],"heart":[132],"rate":[133],"variability":[134],"(HRV)":[135],"monitoring":[136,154],"where":[137],"depressed":[138],"HRV":[139,153],"associated":[141],"poor":[143],"outcomes":[145],"after":[146,169],"MI":[147],"the":[150,256],"general":[151],"population.":[152],"novel":[157],"approach":[158],"Methods:":[162],"Patients":[163,221,248],"prostatic":[165],"adenocarcinoma,":[166],"rising":[167],"PSA":[168,177,298,303],"primary":[170,286],"local":[171],"surgery,":[174],"doubling":[178],"time":[179],"<":[181],"6":[182,213],"months":[183,236],"evidence":[185],"disease":[188],"eligible.":[190],"All":[191],"must":[193],"have":[194,322],"adequate":[195],"function":[197],"Karnofsky":[200],"PS":[201],"\u2265":[202],"70%.":[203],"Exclusions":[204],"include":[205],"MI,":[206],"thromboembolic,":[207],"major":[209],"hemorrhagic":[210],"event":[211],"within":[212],"60":[215],"planned":[218],"enrollment.":[220],"receive":[222,249],"BEV":[223],"15":[224],"mg/kg":[225],"every":[226,234],"3":[227,235,238],"weeks":[228],"(leuprolide":[231],"goserelin)":[233],"cycles":[239],"(1":[240],"cycle":[241],"=":[242],"12":[243],"weeks;":[244],"total":[245],"36":[246],"weeks).":[247],"bicalutamide":[250],"50":[251],"mg":[252],"PO":[253],"daily":[254],"first":[257],"4":[258],"weeks.":[259],"status":[261],"assessed":[263],"by":[264],"serial":[265],"biomarkers,":[267],"echocardiogram":[268],"(week":[269,278],"0":[270],"37)":[272,282],"24-hour":[274],"Holter":[275],"monitor":[276],"testing":[277],"0,":[279],"15,":[280],"HRV.":[284],"The":[285,294],"endpoint":[287,296],"outcome":[290],"adverse":[292],"events.":[293],"secondary":[295],"kinetics":[299],"response.":[304],"Correlative":[305],"cytokine,":[309],"circulating":[310],"cell,":[312],"signaling":[315],"protein":[316],"levels":[317],"planned.":[319],"Six":[320],"been":[323],"enrolled":[324],"date.":[326],"Author":[327],"Disclosure":[328],"Employment":[329],"Leadership":[331],"Position":[332],"Consultant":[333],"Advisory":[335],"Role":[336],"Stock":[337],"Ownership":[338],"Honoraria":[339],"Research":[340],"Funding":[341],"Expert":[342],"Testimony":[343],"Other":[344],"Remuneration":[345],"Genentech":[346]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-09-29T14:09:16.559479","created_date":"2017-03-03T00:00:00"}